ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as Chief Scientific Officer (“CSO”), effective immediately.
As CSO, Dr Jupp will be responsible for overseeing the scientific strategy and research and development activities, focusing on advancing the Company’s innovative polyNaut® platform. He will further lead efforts to expand the pipeline of therapies in a number of indications including but not limited to central nervous system (CNS) diseases.
Dr Jupp brings over 25 years of leadership experience across both biotech and pharmaceutical industries. Before joining ViaNautis, he served as CSO at Mestag Therapeutics, Enara Bio and TRex Bio. Earlier in his career, Dr Jupp held senior positions at UCB, Roche and Sanofi where he moved over 10 compounds into clinical development. Dr Jupp holds a PhD in Biochemistry from Cardiff University and completed a post-doctoral fellowship at the Scripps Research Institute in San Diego.
Dr Ray Jupp, Chief Scientific Officer of ViaNautis, commented:
Joining ViaNautis presents a unique opportunity to advance the development of the Company’s groundbreaking polyNaut® platform. Designed to overcome the challenges of delivering genetic nanomedicines, this innovative technology will enable the creation of precise and targeted treatments to specific tissues and cell types for diseases with significant unmet clinical needs. PolyNaut® has already shown differentiated data in CNS in crossing the blood brain barrier more efficiently than other approaches and look forward to working with the team to advance our pipeline and bring these potentially transformative therapies to patients.
Dr Adi Hoess, Chief Executive Officer of ViaNautis, said:
Ray’s track record of moving multiple compounds into clinical development, coupled with his proven leadership, will be invaluable as we continue to expand our pipeline of therapies through the polyNaut® platform. His leadership will be instrumental in advancing our groundbreaking targeted polymer-based nanovesicles and exploring new therapeutic opportunities.